SCHEMBL4464537

SCHEMBL4464537

NCC(=O)NS(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 7/20 0.70
CA2 P00918 7/20 0.70
ALDH1A1 P00352 2/20 0.66
DHFR P00374 1/20 0.62
TSHR P16473 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
MEN1 O00255 1/20 0.56
LMNA P02545 1/20 0.56
KMT2A Q03164 1/20 0.56
FBP1 P09467 1/20 0.55
MMP1 P03956 1/20 0.55
MMP2 P08253 1/20 0.55
MMP9 P14780 1/20 0.55
MMP8 P22894 1/20 0.55
MMP13 P45452 1/20 0.55
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.49
EGFR P00533 3/20 0.47
ERBB2 P04626 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15650208 0.84 ALDH1A1 (0.69) CA1CA2ALDH1A1DHFRTSHR
SCHEMBL4819815 0.84 ALDH1A1 (0.64) CA1CA2ALDH1A1DHFRTSHR
SCHEMBL6850444 0.84 EGFR (0.68) CA1CA2ALDH1A1TSHRSMN1; SMN2
SCHEMBL13537908 0.84 CA1 (0.68) CA1CA2ALDH1A1TSHRTDP1
SCHEMBL3928646 0.84 EGFR (0.68) CA1CA2ALDH1A1MMP1MMP2
SCHEMBL3928657 0.83 CA1 (0.67) CA1CA2SMN1; SMN2MEN1LMNA
SCHEMBL5458800 0.81 ALDH1A1 (0.65) CA1CA2ALDH1A1DHFRTSHR
SCHEMBL6848813 0.81 CA1 (0.64) CA1CA2MMP1MMP2MMP9
SCHEMBL6850082 0.81 CA1 (0.64) CA1CA2ALDH1A1TDP1MMP1
SCHEMBL3928427 0.80 EGFR (0.63) CA1CA2ALDH1A1LMNAMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625917-B2 S-o-(phenylaminocarbonyl)phenyl-substituted, especially with a quaternary onium group; enhanced antiviral activity and better reactivity with zinc finger moieties, particularly, the zinc finger on HIV-1's NCp7 nucleocapsid protein TURPIN JAMES A 2009-12-01 US disclosed
EP-1087941-B9 THIOLESTERS AND USES THEREOF US HEALTH (US) 2007-11-07 EP disclosed
EP-1087941-B1 THIOLESTERS AND USES THEREOF US HEALTH (US) 2006-08-16 EP disclosed
US-20040132785-A1 Thiolesters and uses thereof The Government of the U. S.of America as Represented by The Sec. of Health and Human Svc. (US) 2004-07-08 US disclosed
US-6706729-B1 A METHOD FOR DISSOCIATING A METAL ION FROM A ZINC FINGER-CONTAINING PROTEIN; INHIBITING VIRUS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2004-03-16 US disclosed
EP-1087941-A2 THIOLESTERS AND USES THEREOF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) 2001-04-04 EP disclosed
WO-1999065871-A2 THIOLESTERS AND USES THEREOF THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132785-A1 Thiolesters and uses thereof SARS1, HAVCR2, P4HB CA1 3728/4885CA2 4550/4885ALDH1A1 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.